SNY - Sanofi
| Previous Close | 42.57 |
| Open | 42.71 |
| Bid | 42.68 x 800 |
| Ask | 42.69 x 1000 |
| Day's Range | 42.59 - 43.03 |
| 52 Week Range | 40.00 - 45.62 |
| Volume | 387,520 |
| Avg. Volume | 1,562,773 |
| Market Cap | 107.201B |
| Beta (3Y Monthly) | 0.44 |
| PE Ratio (TTM) | 22.00 |
| EPS (TTM) | 1.94 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.74 (4.09%) |
| Ex-Dividend Date | 2019-05-07 |
| 1y Target Est | 52.00 |
- Zacks
Pfizer's Xtandi Label Expansion Filing Gets Priority Review
If data from ARCHES study is approved to be included in the label of Pfizer's (PFE) Xtandi, it can treat a broader prostate cancer patient population.
- Zacks
Is Sanofi (SNY) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- MoneyShow
Three Value Stocks for Global Gains
We continue to believe that equities are the place to be for those with the stomach and time horizon to ride out the current trade turbulence and navigate the headwinds that constantly blow both in the U.S. and around the world, asserts John Buckingham, money manager and editor of The Prudent Speculator.
- Benzinga
Biotech Stock On The Radar: Medicines Company, A Cardiovascular Pure Play With A Potential Blockbuster
The Medicines Company (NASDAQ: MDCO) stock has staged a nice recovery in the first half of 2019 after a steep 60% pullback in the second half of 2018 that dragged it to a 52-week low of $16.69 on Dec. 21. Medicines Co. is a biopharma with a single-point focus of tackling cardiovascular diseases. About 17.3 million deaths occur globally due to cardiovascular diseases, with 854,000 of these in the U.S., according to the company, which cited WHO estimates.
- Zacks
Inovio Ends Enrollment in Anal Dysplasia Study on VGX-3100
Inovio (INO) closes enrollment in the phase II study evaluating VGX-3100 for the treatment of HPV-related high-grade anal dysplasia. Shares up.
- Zacks
Regeneron Gets FDA Nod for Eylea Injection Prefilled Syringe
Regeneron (REGN) receives FDA approval for a prefilled syringe of its ophthalmology drug, Eylea.
- Zacks
Should Value Investors Consider Sanofi (SNY) Stock Now?
Let's see if Sanofi (SNY) stock is a good choice for value-oriented investors right now from multiple angles.
- Simply Wall St.
Does Sanofi's (EPA:SAN) CEO Pay Matter?
In 2015 Olivier Brandicourt was appointed CEO of Sanofi (EPA:SAN). First, this article will compare CEO compensation...
- Zacks
J&J's Tuberculosis Drug Gets FDA Nod for Adolescent Patients
FDA approves J&J's (JNJ) pulmonary multidrug-resistant tuberculosis tablet Sirturo (bedaquiline) for the treatment of adolescent patients.
- Reuters
No-deal Brexit could deepen Europe's shortage of medicines - experts
As the Oct. 31 deadline for Britain to leave the European Union approaches, health professionals are warning that shortages of some medicines could worsen in Europe in the event of a no-deal Brexit. Britain's food and drink lobby warned last week that the country would experience shortages of some fresh foods if there is a disorderly no-deal Brexit.
- Zacks
Inovio (INO) Q2 Earnings & Revenues Fall Shy of Estimates
Inovio Pharmaceuticals (INO) disappoints with earnings and revenue miss in the second quarter. Shares depreciate in after-hours trading.
- Zacks
Pharma Stock Roundup: AGN, NVO Earnings, EU Nod to SNY & ABBV Drugs for New Patients
Allergan (AGN) and Novo Nordisk (NVO) report Q2 results. AbbVie's (ABBV) Maviret and Sanofi's (SNY) Dupixent receive approval for new patient population in Europe.
Motley FoolMyoKardia, Inc. (MYOK) Q2 2019 Earnings Call Transcript
MYOK earnings call for the period ending June 30, 2019.
- Motley Fool
3 Dividend Stocks That Pay You More Than Pepsi Does
Sanofi, Realty Income, and Dick's Sporting Goods might just serve up more refreshing returns than the beverage giant.
- Zacks
Alnylam's (ALNY) Q2 Earnings and Revenues Miss Estimates
Alnylam (ALNY) incurs wider-than-expected loss and misses sales estimates in the second quarter of 2019.
- Motley Fool
Regeneron Pharmaceuticals Reports Marked Improvement in Q2
Revenue and earnings beat Wall Street estimates thanks to solid growth for Eylea and Dupixent.
- Zacks
Regeneron (REGN) Q2 Earnings Top Estimates, Eylea Sales Solid
Regeneron (REGN) tops on Q2 earnings and sales in the second quarter on the back of solid demand for ophthalmology drug, Eylea, and asthma drug, Dupixent.
- Motley Fool
BioMarin's Roller Coaster Continues
Long-term investors need to learn to stomach the ride.
- Zacks
SNY vs. PFE: Which Stock Is the Better Value Option?
SNY vs. PFE: Which Stock Is the Better Value Option?
- Zacks
Are Investors Undervaluing Sanofi (SNY) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- MarketWatch
Regeneron stock up 2.2% after earnings beat
Shares of Regeneron Pharmaceuticals Inc. rose 2.2% in premarket trade Tuesday after the company reported second-quarter earnings that beat analysts' expectations. Profit in the latest quarter fell to $193 million, or $1.68 a share, from $551 million, or $4.82 a share, a year ago. Adjusted EPS was $6.02 a share, topping the FactSet consensus of $5.42 a share. Revenue came in at $1.934 billion, compared with $1.608 billion in the year-earlier quarter, beating the FactSet consensus of $1.804 billion. Regeneron derives revenue from its own discovered products and from collaborations with Sanofi and Bayer AG . Revenue from Regeneron's own products grew to $1.205 billion in the latest quarter -- which included U.S. sales of $1.16 billion from the company's eye drug Eylea -- from $996.4 million in the year-earlier quarter. Sales of Eylea outside the U.S. came to $715.3 million and were booked by Bayer. Revenue from Regeneron's Sanofi collaboration rose to $349.1 million from $237.8 million a year ago, while revenue from the Bayer collaboration grew to $289 million from $262.9 million a year ago. Shares of Regeneron have fallen 20% in the year to date through Monday, while the S&P 500 has gained 13.5%.
- Benzinga
The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks No biotech stocks hit 52-week highs Monday. Down In The Dumps (Biotech stocks hitting 52-week lows on ...
- Reuters
UPDATE 1-EU approves Sanofi, Regeneron's Dupixent for adolescent eczema cases
The Dupixent product developed by French healthcare company Sanofi and its U.S. partner Regeneron has won regulatory approval in Europe for moderate-to-severe cases of eczema in adolescents, the companies said. The European Commission has extended the marketing authorisation for Dupixent in the European Union to include adolescents 12 to 17 years of age with moderate-to-severe atopic dermatitis who are candidates for systemic therapy, Sanofi and Regeneron said in a joint statement on Tuesday.
- Reuters
EU regulators approve Sanofi, Regeneron's Dupixent for adolescent cases
The Dupixent product developed by French healthcare company Sanofi and its U.S. partner Regeneron has won approval in Europe for adolescents with moderate-to-severe atopic dermatitis, the companies said on Tuesday. The European Commission has extended the marketing authorisation for Dupixent in the European Union to include adolescents 12 to 17 years of age with moderate-to-severe atopic dermatitis who are candidates for systemic therapy, Sanofi and Regeneron said in a joint statement.
Motley FoolSanofi (SNY) Q2 2019 Earnings Call Transcript
SNY earnings call for the period ending June 30, 2019.
